Actavis launched Risperidone tablets on day one in a number of European countries, including Germany, the UK, Netherlands and Denmark.

Medis, Actavis’ third party sales division, has also launched Risperidone in various markets, including France and Germany. Earlier in 2007 Actavis marketed Risperidone in Turkey and Romania. Medis had previously launched Risperidone in Portugal, Poland and other countries in 2006.

Risperidone, the generic version of Janssen Pharmaceutica’s Risperdal®, is produced in 0,25mg, 0,5mg, 1mg, 2mg, 3mg, 4 mg and 6mg strengths by Actavis. The product was developed by Actavis R&D and manufactured in Iceland.

Risperidone is used to treat the symptoms of psychotic disorders, such as schizophrenia, mania or bipolar disorder, or irritability associated with autistic disorder.

Annual sales of Risperidone amounted to about 1bn EUR in the European Economic Area (APR 2006 – MAR 2007), according to IMS Health data.